CIK 0001672619
- Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811523849
- Phone
- +1 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $22.49 ($269,841)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 4,250 shares at $22.54 ($95,782)
- 4 Planned sale PRESIDENT AND CEO sold 12,000 shares at $22.89 ($274,718)
- 4 Planned sale Director sold 1,270 shares at an average $23.25 ($29,526)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 3,099 shares at $27.56 ($85,399)
- 4 Planned sale PRESIDENT AND CEO sold 2,270 shares at $27.56 ($62,555)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 991 shares at $27.53 ($27,281)
- 4 Planned sale Director sold 2,351 shares at an average $27.50 ($64,663)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $26.70 ($320,378)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 5,250 shares at an average $26.68 ($140,052)
- 4 Planned sale PRESIDENT AND CEO sold 12,000 shares at an average $24.92 ($299,073)
- 4 Planned sale Director sold 1,270 shares at $24.80 ($31,497)
- 4 Planned sale CHIEF OPERATING OFFICER sold 50,000 shares at an average $25.06 ($1,252,826)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,000 shares at $25.07 ($75,195)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at $22.89 ($274,736)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 4,250 shares at an average $22.57 ($95,922)
- 4 Planned sale PRESIDENT AND CEO sold 12,000 shares at an average $21.66 ($259,902)
- 4 Planned sale Director sold 1,270 shares at $21.48 ($27,278)
- 4 Planned sale CHIEF OPERATING OFFICER sold 1,133 shares at $20.06 ($22,722)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $21.73 ($260,800)
Page 8 of 20 · 383 filings